Q-omics provides the consensus-scored HCRTR1 profile across patient tissues and cancer cell-line models. HCRTR1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HCRTR1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, HCRTR1 RNA expression shows 17,976 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where HCRTR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HCRTR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HCRTR1 survival associations across molecular data types. HCRTR1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HCRTR1 RNA expression–survival associations across cancer types. High HCRTR1 expression shows unfavorable associations in COAD, KIRC, UVM and LIHC, but favorable associations in HNSC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for HCRTR1 RNA expression.
This table summarizes HCRTR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HCRTR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HCRTR1 shows lower tumor expression in KIRC, THCA, KICH, BRCA, UCEC and KIRP. The KIRC box plot shows higher HCRTR1 RNA expression in normal versus tumor tissue (log2 FC = −0.162, t-test p < 0.001).
This table shows molecular features associated with HCRTR1 in patient tissues and cancer cell lines. In patient samples, HCRTR1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HCRTR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and OVARY.
